-
Innovation Ranking
Innovation Ranking – Voyager Therapeutics Inc
Voyager Therapeutics Inc (Voyager) is a gene therapy company that discovers, develops and commercializes therapies to treat severe neurological diseases. It is evaluating VY-AADC program for the treatment of advanced Parkinson’s disease; VY-SOD102 against monogenic amyotrophic lateral sclerosis (ALS); VY-HTT01 to treat Huntington’s disease and VY-FXN01 program targeting Friedreich's ataxia. The company is also investigating therapies against tauopathies including Alzheimer’s disease (AD), frontotemporal lobar degeneration (FTD), Pick’s disease, progressive supranuclear palsy (PSP) and corticobasal degeneration. It works in collaboration with...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Solid Tumor Drug Details: Voyager-V1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Colorectal Cancer Drug Details: Voyager-V1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Endometrial Cancer Drug Details: Voyager-V1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Relapsed Multiple Myeloma Drug Details: Voyager-V1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Refractory Multiple Myeloma Drug Details: Voyager-V1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Non-Small Cell Lung Cancer Drug Details: Voyager-V1 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Voyager-V1 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Voyager-V1 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Voyager-V1 in Head And Neck Squamous...
-
Product Insights
NewEMulate Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our EMulate Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. EMulate Therapeutics Inc (EMulate Therapeutics), formerly known as Nativis Inc, is a clinical stage bio-electronics company. The company provides portfolio of pipeline candidates which are under development for various therapeutic areas such as recurrent glioblastoma, brain metastisis, pain, rheumatoid arthritis, lung cancer and melanoma, among others. Its lead product, EMulate Therapeutics Voyager device is being evaluated for the treatment...